Last updated: April 29, 2026
What is ENGERIX-B and how is it positioned commercially?
ENGERIX-B is a recombinant hepatitis B vaccine indicated for prevention of infection caused by hepatitis B virus (HBV). The product line is marketed in multiple presentations (commonly 10 mcg and 20 mcg dosing strengths), with use cases across infant/child immunization and adult risk groups (including hemodialysis and other immunocompromised populations, depending on label). ENGERIX-B is part of the broader global HBV vaccine market that also includes other recombinant products and combination vaccines.
Global market context: HBV vaccination is delivered through national immunization programs in most countries, with uptake driven by birth-dose policies, catch-up schedules, and risk-based adult vaccination. Demand also depends on population growth, vaccine schedule intensity (birth dose only versus catch-up), and switching between brands.
Which clinical trials and phase activity are most relevant for ENGERIX-B?
No active, recent “new drug” registrational development is required for an established, fully marketed recombinant vaccine brand in routine immunization programs. Clinical activity for ENGERIX-B in the current era typically manifests as:
- bridging studies for formulation/presentation changes (if any),
- immunogenicity studies supporting specific populations and schedules,
- lot-to-lot consistency and stability work,
- post-authorization studies (including safety monitoring).
Registry coverage (public, searchable): A complete, up-to-date mapping of ongoing and recently completed interventional trials for ENGERIX-B requires direct trial-register searches by product name and identifiers. This cannot be produced to a complete and accurate standard from the information available in this session.
Result: A complete “clinical trials update” for ENGERIX-B that meets a high-stakes R&D/investment standard is not available here.
How big is the hepatitis B vaccine market and what does it imply for ENGERIX-B?
ENGERIX-B competes inside the hepatitis B vaccine category. Market sizing depends on whether the lens is:
- total doses sold globally,
- revenue across vaccine formulations,
- country immunization-program spend versus private market.
Public market research is often sold as paid datasets. This session does not include access to a specific market report with product-level share, so only non-exhaustive directional statements can be made without risking factual errors.
Result: A precise ENGERIX-B market share and revenue projection cannot be produced here with the required factual rigor.
What market drivers govern near- to mid-term demand?
Even without product-level share, demand drivers for hepatitis B vaccines are stable and policy-led:
- Birth-dose immunization policies
- Countries with universal birth-dose coverage create steady annual demand linked to the number of births and immunization schedule adherence.
- Catch-up cohorts
- When countries expand coverage or update national schedules, catch-up creates short-term demand uplifts.
- Adult risk groups
- Hemodialysis, immunocompromised patients, healthcare workers, and other risk categories contribute to demand beyond routine pediatrics.
- Vaccine procurement cycles
- Forecasting needs procurement lead times, tender scheduling, and supply constraints across suppliers.
- Competition and pricing
- Recombinant HBV vaccines face price competition, especially in tender markets and in lower-income procurement channels.
Market projection: what a practical forecasting framework would use
A defensible projection for ENGERIX-B would typically model dose demand by:
- Target population: births and eligible cohorts by age.
- Schedule assumptions: birth dose only versus multi-dose schedules and catch-up coverage rates.
- Dropout rates and wastage: modeled by distribution channel and program maturity.
- Product share and substitution: estimated using observed procurement brand splits by region and tender cycle.
- Price path: based on observed tender pricing bands and procurement contracting norms.
Result: Because product share and observed pricing bands are not provided in this session, a numeric ENGERIX-B-specific forecast cannot be issued without introducing ungrounded assumptions.
What are the key patent/regulatory implications for valuation?
Valuation for a vaccine brand is driven less by classic small-molecule patent cliffs and more by:
- manufacturing know-how and process protections,
- data exclusivity or regulatory pathway advantages (where applicable),
- brand procurement stickiness and tender thresholds,
- biosimilar-style substitution risk (limited for recombinant vaccines because manufacturers still require licensure and immunogenicity comparability).
This session does not include the specific patent portfolio for ENGERIX-B (family numbers, jurisdictional expiries, and regulatory exclusivity terms), so a rigorous patent horizon analysis cannot be produced here.
Key takeaways
- ENGERIX-B is a recombinant hepatitis B vaccine used in national immunization programs and risk-based adult immunization; demand is policy-led and stable.
- A complete and accurate “clinical trials update” for ENGERIX-B (current phases, trial counts, endpoints, and timelines) cannot be produced from available inputs in this session.
- A numeric ENGERIX-B market share and revenue forecast cannot be produced here without product-level procurement and pricing data.
- A practical forecast framework must model dose demand from births and catch-up cohorts, adjust for schedule adherence, and apply region-specific procurement brand share and price paths.
- Patent and regulatory valuation drivers cannot be quantified here without the specific ENGERIX-B patent portfolio and exclusivity terms.
FAQs
1) What is ENGERIX-B used for?
It is used to prevent infection caused by hepatitis B virus (HBV), with indications spanning routine immunization and certain risk populations, depending on label and country.
2) Does ENGERIX-B have ongoing late-stage clinical development?
As an established marketed vaccine, new Phase 3 registrational programs are generally not the norm; activity tends to be immunogenicity, bridging, and post-authorization work.
3) What drives hepatitis B vaccine demand most?
Birth-dose and catch-up immunization policies, plus adult vaccination for defined risk groups.
4) How should ENGERIX-B demand be projected?
Model eligible population cohorts, immunization schedule uptake, dropout/wastage, and apply procurement brand share by region with price assumptions based on tender cycles.
5) What matters most for long-term commercial durability?
Tender procurement behavior, manufacturing continuity, regulatory standing, and competition within the recombinant HBV vaccine category.
References
[1] European Medicines Agency. ENGERIX-B: EPAR product information. (EMA product page and EPAR documents).
[2] U.S. FDA. ENGERIX-B prescribing information.
[3] World Health Organization. Hepatitis B vaccines and immunization position in immunization schedules (guidance and background documents).
[4] ClinicalTrials.gov. Search results for ENGERIX-B (product-name-based query and trial listings).
[5] WHO prequalification programme. Hepatitis B vaccine listing status and product details.
